Table 3. Pooled estimates of clinical... | American Society of Hematology

Table 3.

Pooled estimates of clinical events in studies comparing DOACs vs warfarin in patients with concomitant valve disease and AF

	Total patients, n	OR, events per test period			Heterogeneity
	Total patients, n	OR	95% CI	P value	Q test, P value	Higgins I², %
No. of bleeds
Overall bleeds
RCTs	6 851	0.89	0.61-1.31	.56	.04	63
Non-RCTs	91 596	0.75	0.57-0.97	.03	<.01	91
Non-RCTs (apixaban only)	18 663	0.28	0.01-9.56	.48	.01	84
GI bleeds, non-RCTs	40 206	0.47	0.07-3.23	.44	<.01	100
Intracranial bleeds, non-RCTs	23 683	0.45	0.31-0.64	<.01	.16	35
Stroke incidence
RCTs	2 123	0.87	0.56-1.36	.54	.59	0
Non-RCTs	94 352	0.66	0.47-0.93	.02	<.01	89
TIAs, non-RCTs	17 562	1.11	0.85-1.45	.81	.12	45
Systemic/arterial embolism, non-RCTs	3 872	2.18	0.89-5.32	.09	.77	0
All-cause mortality
RCTs	2 123	0.89	0.67-1.17	.40	.75	0
Non-RCTs	78 418	0.77	0.54-1.09	.14	<.01	93

	Total patients, n	OR, events per test period			Heterogeneity
	Total patients, n	OR	95% CI	P value	Q test, P value	Higgins I², %
No. of bleeds
Overall bleeds
RCTs	6 851	0.89	0.61-1.31	.56	.04	63
Non-RCTs	91 596	0.75	0.57-0.97	.03	<.01	91
Non-RCTs (apixaban only)	18 663	0.28	0.01-9.56	.48	.01	84
GI bleeds, non-RCTs	40 206	0.47	0.07-3.23	.44	<.01	100
Intracranial bleeds, non-RCTs	23 683	0.45	0.31-0.64	<.01	.16	35
Stroke incidence
RCTs	2 123	0.87	0.56-1.36	.54	.59	0
Non-RCTs	94 352	0.66	0.47-0.93	.02	<.01	89
TIAs, non-RCTs	17 562	1.11	0.85-1.45	.81	.12	45
Systemic/arterial embolism, non-RCTs	3 872	2.18	0.89-5.32	.09	.77	0
All-cause mortality
RCTs	2 123	0.89	0.67-1.17	.40	.75	0
Non-RCTs	78 418	0.77	0.54-1.09	.14	<.01	93

Unless a specific DOAC is indicated in brackets (apixaban, edoxaban, or rivaroxaban only), the result represents a pooled estimate for all DOACs.